Variants on the promoter region of PTEN affect breast cancer progression and patient survival

Breast Cancer Research

Volumn 13, Issue 6, 2011, Pages

  Heikkinen, Tuomas ^a   Greco, Dario ^a   Pelttari, Liisa M ^a   Tommiska, Johanna ^a   Vahteristo, Pia ^a   Heikkilä, Päivi ^a   Blomqvist, Carl ^a   Aittomäki, Kristiina ^a   Nevanlinna, Heli ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; PROMOTER REGION; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; CLUSTER ANALYSIS; DISEASE COURSE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; MORTALITY; PROGNOSIS; SURVIVAL;

BREAST NEOPLASMS; CLUSTER ANALYSIS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS, GENETIC; PTEN PHOSPHOHYDROLASE; SURVIVAL ANALYSIS;

EID: 83455162719     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3076     Document Type: Article

References (52)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71. 10.1126/science.7545954, 7545954.
2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792. 10.1038/378789a0, 8524414.
3. Lee EH, Park SK, Park B, Kim SW, Lee MH, Ahn SH, Son BH, Yoo KY, Kang D, , . KOHBRA Research Group, Korean Breast Cancer Society Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res Treat 2010, 122:11-25. 10.1007/s10549-010-0859-2, 20376556, KOHBRA Research Group, Korean Breast Cancer Society.
4. Heikkinen T, Karkkainen H, Aaltonen K, Milne RL, Heikkila P, Aittomaki K, Blomqvist C, Nevanlinna H. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res 2009, 15:3214-3222. 10.1158/1078-0432.CCR-08-3128, 19383810.
5. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238. 10.1126/science.1978757, 1978757.
6. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimaki A, von Smitten K, Aittomaki K, Heikkila P, Blomqvist C, Nevanlinna H. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 2005, 11:5098-5103. 10.1158/1078-0432.CCR-05-0173, 16033823.
7. Schmidt MK, Tommiska J, Broeks A, van Leeuwen FE, Van't Veer LJ, Pharoah PD, Easton DF, Shah M, Humphreys M, Dork T, Reincke SA, Fagerholm R, Blomqvist C, Nevanlinna H. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res 2009, 11:R89. 10.1186/bcr2460, 2815553, 20021639.
8. Nelen MR, Padberg GW, Peeters EA, Lin AY, van den Helm B, Frants RR, Coulon V, Goldstein AM, van Reen MM, Easton DF, Eeles RA, Hodgsen S, Mulvihill JJ, Murday VA, Tucker MA, Mariman EC, Starink TM, Ponder BA, Ropers HH, Kremer H, Longy M, Eng C. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996, 13:114-116. 10.1038/ng0596-114, 8673088.
9. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997, 16:64-67. 10.1038/ng0597-64, 9140396.
10. Eng C. Constipation, polyps, or cancer? Let PTEN predict your future. Am J Med Genet A 2003, 122A:315-322. 10.1002/ajmg.a.20477, 14518069.
11. Teresi RE, Zbuk KM, Pezzolesi MG, Waite KA, Eng C. Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. Am J Hum Genet 2007, 81:756-767. 10.1086/521051, 2227925, 17847000.
12. Zhou XP, Waite KA, Pilarski R, Hampel H, Fernandez MJ, Bos C, Dasouki M, Feldman GL, Greenberg LA, Ivanovich J, Matloff E, Patterson A, Pierpont ME, Russo D, Nassif NT, Eng C. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet 2003, 73:404-411. 10.1086/377109, 1180378, 12844284.
13. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW. Regulation of PTEN transcription by p53. Mol Cell 2001, 8:317-325. 10.1016/S1097-2765(01)00323-9, 11545734.
14. Sheng X, Koul D, Liu JL, Liu TJ, Yung WK. Promoter analysis of tumor suppressor gene PTEN: identification of minimum promoter region. Biochem Biophys Res Commun 2002, 292:422-426. 10.1006/bbrc.2002.6662, 11906179.
15. Carroll BT, Couch FJ, Rebbeck TR, Weber BL. Polymorphisms in PTEN in breast cancer families. J Med Genet 1999, 36:94-96. 1734307, 10051004.
16. Haiman CA, Stram DO, Cheng I, Giorgi EE, Pooler L, Penney K, Le Marchand L, Henderson BE, Freedman ML. Common genetic variation at PTEN and risk of sporadic breast and prostate cancer. Cancer Epidemiol Biomarkers Prev 2006, 15:1021-1025. 10.1158/1055-9965.EPI-05-0896, 16702386.
17. Guenard F, Labrie Y, Ouellette G, Beauparlant CJ, Bessette P, Chiquette J, Laframboise R, Lepine J, Lesperance B, Pichette R, Plante M, Durocher F, . INHERIT BRCAs Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families. Fam Cancer 2007, 6:483-490. 10.1007/s10689-007-9151-y, 17636424, INHERIT BRCAs.
18. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947. 10.1126/science.275.5308.1943, 9072974.
19. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997, 15:356-362. 10.1038/ng0497-356, 9090379.
20. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999, 96:4240-4245. 10.1073/pnas.96.8.4240, 33561, 10200246.
21. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430. 10.1038/nature04869, 16724053.
22. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008, 133:403-414. 10.1016/j.cell.2008.04.013, 18455982.
23. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL, Eng C. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999, 155:1253-1260. 10.1016/S0002-9440(10)65227-3, 1867038, 10514407.
24. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001, 14:672-676. 10.1038/modpathol.3880371, 11454999.
25. Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol 2002, 33:405-409. 10.1053/hupa.2002.124721, 12055674.
26. Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era S, Mori M. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 2005, 68:398-404. 10.1159/000086981, 16020969.
27. Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE, Skoog L, Stal O. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007, 13:3577-3584. 10.1158/1078-0432.CCR-06-1609, 17575221.
28. Lopez-Knowles E, O'Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P, Daly RJ, Musgrove EA, Sutherland RL. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010, 126:1121-1131.
29. Saal LH, Gruvberger-Saal SK, Persson C, Lovgren K, Jumppanen M, Staaf J, Jonsson G, Pires MM, Maurer M, Holm K, Koujak S, Subramaniyam S, Vallon-Christersson J, Olsson H, Su T, Memeo L, Ludwig T, Ethier SP, Krogh M, Szabolcs M, Murty VV, Isola J, Hibshoosh H, Parsons R, Borg A. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008, 40:102-107. 10.1038/ng.2007.39, 3018354, 18066063.
30. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmstrom P, Memeo L, Isola J, Bendahl PO, Rosen N, Hibshoosh H, Ringner M, Borg A, Parsons R. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007, 104:7564-7569. 10.1073/pnas.0702507104, 1855070, 17452630.
31. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E, Richardson AL, Zhang J, Pandolfi PP. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 2010, 42:454-458. 10.1038/ng.556, 3118559, 20400965.
32. Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, Holli K, Blomqvist C, Kallioniemi OP, Kainu T, Nevanlinna H. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000, 92:1529-1531. 10.1093/jnci/92.18.1529, 10995809.
33. Kilpivaara O, Bartkova J, Eerola H, Syrjakoski K, Vahteristo P, Lukas J, Blomqvist C, Holli K, Heikkila P, Sauter G, Kallioniemi OP, Bartek J, Nevanlinna H. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 2005, 113:575-580. 10.1002/ijc.20638, 15472904.
34. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjakoski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma VM, Uusitupa M, Eskelinen M, Kataja V, Aittomaki K, von Smitten K, Heikkila P, Lukas J, Holli K, Bartkova J, Blomqvist C, Bartek J, Nevanlinna H. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008, 40:844-853. 10.1038/ng.155, 18511948.
35. Vahteristo P, Eerola H, Tamminen A, Blomqvist C, Nevanlinna H. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 2001, 84:704-708. 10.1054/bjoc.2000.1626, 2363799, 11237395.
36. Eerola H, Heikkila P, Tamminen A, Aittomaki K, Blomqvist C, Nevanlinna H. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2005, 7:R93-100. 10.1186/bcr953, 1064101, 15642173.
37. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
38. Tommiska J, Bartkova J, Heinonen M, Hautala L, Kilpivaara O, Eerola H, Aittomaki K, Hofstetter B, Lukas J, von Smitten K, Blomqvist C, Ristimaki A, Heikkila P, Bartek J, Nevanlinna H. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene 2008, 27:2501-2506. 10.1038/sj.onc.1210885, 17982490.
39. Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjallskog ML, Blomqvist C. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values?. Histopathology 2007, 51:491-498. 10.1111/j.1365-2559.2007.02798.x, 17711446.
40. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80. 10.1186/gb-2004-5-10-r80, 545600, 15461798.
41. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008, 24:1547-1548. 10.1093/bioinformatics/btn224, 18467348.
42. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193. 10.1093/bioinformatics/19.2.185, 12538238.
43. Smyth GK. Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor 2005, 397-420. New York: Springer, Gentleman R, Carey V, Dudoit S, Irizarry WH R.
44. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
45. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, Smeds J, Skoog L, Wedren S, Bergh J. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005, 7:R953-964. 10.1186/bcr1325, 1410752, 16280042.
46. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, Wong JE, Liu ET, Bergh J, Kuznetsov VA, Miller LD. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006, 66:10292-10301. 10.1158/0008-5472.CAN-05-4414, 17079448.
47. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
48. Carracedo A, Alimonti A, Pandolfi PP. PTEN level in tumor suppression: How much is too little?. Cancer Res 2011, 17:629-633.
49. Fritzmann J, Morkel M, Besser D, Budczies J, Kosel F, Brembeck FH, Stein U, Fichtner I, Schlag PM, Birchmeier W. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. Gastroenterology 2009, 137:165-175. 10.1053/j.gastro.2009.03.041, 19328798.
50. Khin SS, Kitazawa R, Win N, Aye TT, Mori K, Kondo T, Kitazawa S. BAMBI gene is epigenetically silenced in subset of high-grade bladder cancer. Int J Cancer 2009, 125:328-338. 10.1002/ijc.24318, 19326429.
51. Draghici S, Khatri P, Eklund AC, Szallasi Z. Reliability and reproducibility issues in DNA microarray measurements. Trends Genet 2006, 22:101-109. 10.1016/j.tig.2005.12.005, 2386979, 16380191.
52. Lukes L, Crawford NP, Walker R, Hunter KW. The origins of breast cancer prognostic gene expression profiles. Cancer Res 2009, 69:310-318. 10.1158/0008-5472.CAN-08-3520, 2613551, 19118016.